Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug

References

• SiddiquiN, HusainA, ChaudhryL, AlamMS, MitraM, BhasinPS. Pharmacological and pharmaceutical profile of valsartan: a review. J Appl Pharm Sci. 2011;8.
   Google Scholar
• IsrailiZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000;14 Suppl 1:S73–86. doi:10.1038/sj.jhh.100099110854085
   PubMed Web of Science ®Google Scholar
• MeredithPA. Candesartan cilexetil–a review of effects on cardiovascular complications in hypertension and chronic heart failure. Curr Med Res Opin. 2007;23(7):1693–1705. doi:10.1185/030079907x21072317588300
   PubMed Web of Science ®Google Scholar
• OstergrenJ. Candesartan for the treatment of hypertension and heart failure. Expert Opin Pharmacother. 2004;5(7):1589–1597. doi:10.1517/14656566.5.7.158915212609
   PubMed Web of Science ®Google Scholar
• RossA, PapademetriouV. Candesartan cilexetil in cardiovascular disease. Expert Rev Cardiovasc Ther. 2004;2(6):829–835. doi:10.1586/14779072.2.6.82915500428
   PubMedGoogle Scholar
• RossiS. Australian Medicines Handbook 2006. Australian Medicines Handbook; 2006.
   Google Scholar
• HusainA, AzimM, MitraM, BhasinP. A review on candesartan: pharmacological and pharmaceutical profile. J Appl Pharm Sci. 2011;01:12–17.
   Google Scholar
• VasconcelosT, SarmentoB, CostaP. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12(23–24):1068–1075. doi:10.1016/j.drudis.2007.09.00518061887
   PubMed Web of Science ®Google Scholar
• CagigalE, GonzálezL, AlonsoRM, JiménezRM. pK(a) determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry. J Pharm Biomed Anal. 2001;26(3):477–486. doi:10.1016/s0731-7085(01)00413-711489393
   PubMed Web of Science ®Google Scholar
• SekiguchiK, ObiN. Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull (Tokyo). 1961;9(11):866–872. doi:10.1248/cpb.9.866
   Web of Science ®Google Scholar
• FathanahA, SetyawanD, SariR. Improving solubility and dissolution of meloxicam by solid dispersion using hydroxypropyl methylcellulose 2910 3 cps and nicotinamide. J Basic Clin Physiol Pharmacol. 2019;30. doi:10.1515/jbcpp-2019-0249.
   PubMedGoogle Scholar
• FebriyentiF, RahmiS, HalimA. Study of gliclazide solid dispersion systems using PVP K-30 and PEG 6000 by solvent method. J Pharm Bioallied Sci. 2019;11(3):262–267. doi:10.4103/jpbs.JPBS_87_1831555033
   PubMed Web of Science ®Google Scholar
• RealD, OrzanL, LeonardiD, SalomonCJ. Improving the dissolution of triclabendazole from stable crystalline solid dispersions formulated for oral delivery. AAPS PharmSciTech. 2019;21(1):16. doi:10.1208/s12249-019-1551-431807963
   PubMed Web of Science ®Google Scholar
• DamodharanN. Preparation and evaluation of solid dispersion of candesartan cilexetil. J Pharm Res. 2012;1:5.
   Google Scholar
• SchönbeckC, GaardahlK, HoustonB. Drug solubilization by mixtures of cyclodextrins: additive and synergistic effects. Mol Pharm. 2019;16(2):648–654. doi:10.1021/acs.molpharmaceut.8b0095330608695
   PubMed Web of Science ®Google Scholar
• Mohamed AmeenH, Kunsági-MátéS, BognárB, SzenteL, PoórM, LemliB. Thermodynamic characterization of the interaction between the antimicrobial drug sulfamethazine and two selected cyclodextrins. Molecules. 2019;24(24):4565. doi:10.3390/molecules24244565
   PubMed Web of Science ®Google Scholar
• YousafAM, QadeerA, RazaSA, et al. Influence of levodropropizine and hydroxypropyl-β-cyclodextrin association on the physicochemical characteristics of levodropropizine loaded in hydroxypropyl-β-cyclodextrin microcontainers: formulation and in vitro characterization. Polim Med. 2019;49(1):35–43. doi:10.17219/pim/11188731769938
   PubMedGoogle Scholar
• MaZ, WangN, HeH, TangX. Pharmaceutical strategies of improving oral systemic bioavailability of curcumin for clinical application. J Control Release. 2019;316:359–380. doi:10.1016/j.jconrel.2019.10.05331682912
   PubMed Web of Science ®Google Scholar
• JyothiSA, ReddyBS, NavathaA. Enhancing the solubility of candesartan cilexetil-inclusion complexation using β-CD. Int J Drug Deliv. 2013;5(1):88–93.
   Google Scholar
• UekamaK, HirayamaF, ArimaH. Pharmaceutical applications of cyclodextrins and their derivatives In: DodziukH, editor. Cyclodextrins and Their Complexes. John Wiley & Sons, Ltd; 2006:381–422. doi:10.1002/3527608982.ch14.
   Google Scholar
• CarrierRL, MillerLA, AhmedI. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release. 2007;123(2):78–99. doi:10.1016/j.jconrel.2007.07.01817888540
   PubMed Web of Science ®Google Scholar
• RamaA, VeigaF, FigueiredoI, SousaA, CaramonaM. Biopharmaceutical aspects of formulation of medicines for neonates. Basics of Indomethacin complexation with hydroxypropyl-β-cyclodextrin for oral treatment of ductus arteriosus closure. Braz J Pharm Sci. 2005;41:281.
   Google Scholar
• MüllerRH, JacobsC, KayserO. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3–19. doi:10.1016/S0169-409X(00)00118-611251242
   PubMed Web of Science ®Google Scholar
• MohanrajVJ, ChenY. Nanoparticles - A review. Tropical J Pharm Res. 2006;5(1):561–573. doi:10.4314/tjpr.v5i1.14634
   Google Scholar
• FrancoM, TrapaniG, LatrofaA, et al. Dissolution properties and anticonvulsant activity of phenytoin-polyethylene glycol 6000 and -polyvinylpyrrolidone K-30 solid dispersions. Int J Pharm. 2001;225(1–2):63–73. doi:10.1016/s0378-5173(01)00751-711489555
   PubMed Web of Science ®Google Scholar
• PatelDM, PatelSP, PatelCN. Formulation and evaluation of fast dissolving tablet containing domperidone ternary solid dispersion. Int J Pharm Investig. 2014;4(4):174–182. doi:10.4103/2230-973X.143116
   PubMedGoogle Scholar
• HIGUCHIT. A phase solubility technique. Adv Anal Chem Instrum. 1965;4:117–211.
   Google Scholar
• ReddyMN, RehanaT, RamakrishnaS, ChowdharyKPR, DiwanPV. Beta-cyclodextrin complexes of celecoxib: molecular-modeling, characterization, and dissolution studies. AAPS PharmSci. 2004;6(1):E7. doi:10.1208/ps06010715198508
   PubMed Web of Science ®Google Scholar
• GrilloR, de MeloNFS, MoraesCM, et al. Study of the interaction between hydroxymethylnitrofurazone and 2-hydroxypropyl-β-cyclodextrin. J Pharm Biomed Anal. 2008;47(2):295–302. doi:10.1016/j.jpba.2008.01.01018289821
   PubMed Web of Science ®Google Scholar
• MenniniN, MaestrelliF, CirriM, MuraP. Analysis of physicochemical properties of ternary systems of oxaprozin with randomly methylated-ß-cyclodextrin and l-arginine aimed to improve the drug solubility. J Pharm Biomed Anal. 2016;129:350–358. doi:10.1016/j.jpba.2016.07.02427454086
   PubMed Web of Science ®Google Scholar
• FengL, FawazR, HovdeS, ShengF, NosratiM, GeigerJH. Crystal structures of Escherichia coli branching enzyme in complex with cyclodextrins. Acta Crystallogr D Struct Biol. 2016;72(Pt 5):641–647. doi:10.1107/S205979831600327227139627
   PubMedGoogle Scholar
• AbdelkaderH, FathallaZ, MoharramH, AliTFS, PierscionekB. Cyclodextrin enhances corneal tolerability and reduces ocular toxicity caused by diclofenac. Oxid Med Cell Longev. 2018;2018. doi:10.1155/2018/5260976
   PubMed Web of Science ®Google Scholar
• FernandezD, VegaD, EllenaJ. Candesartan cilexetil, an antihypertensive agent containing an extended double ester chain. Acta Crystallogr Sect E Struct Rep Online. 2005;61. doi:10.1107/S1600536805000097/cv6437Isup2.hkl.
   Google Scholar
• SuriSS, FenniriH, SinghB. Nanotechnology-based drug delivery systems. J Occup Med Toxicol. 2007;2:16. doi:10.1186/1745-6673-2-1618053152
   PubMedGoogle Scholar
• DevalapallyH, ChakilamA, AmijiMM. Role of nanotechnology in pharmaceutical product development. J Pharm Sci. 2007;96(10):2547–2565. doi:10.1002/jps.2087517688284
   PubMed Web of Science ®Google Scholar
• RavalA, PatelM. Preparation and characterization of nanoparticles for solubility and dissolution rate enhancement of meloxicam. Intl R J of Pharm. 2011;1(2):42–49.
   Google Scholar
• LiuT, GuoR. Investigation of PEG 6000/Tween 80/Span 80/H2O niosome microstructure. Colloid Polym Sci. 2007;285(6):711–713. doi:10.1007/s00396-006-1627-z
   Web of Science ®Google Scholar
• AmerAM, AllamAN, AbdallahOY. Evaluation of the discriminatory power of USP dissolution method for candesartan cilexetil tablets through testing of marketed products in Egypt. Dissolution Technol. 2018;25(4):40–46. doi:10.14227/DT250418P40
   Web of Science ®Google Scholar
• National Research Council. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington, DC: The National Academies Press; 2012.
   Google Scholar
• ZhangY, HuoM, ZhouJ, XieS. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel. Comput Methods Programs Biomed. 2010;99(3):306–314. doi:10.1016/j.cmpb.2010.01.00720176408
   PubMed Web of Science ®Google Scholar
• HattoriY, HarunaY, OtsukaM. Dissolution process analysis using model-free Noyes-Whitney integral equation. Colloids Surf B Biointerfaces. 2013;102:227–231. doi:10.1016/j.colsurfb.2012.08.01723010115
   PubMed Web of Science ®Google Scholar
• HunterR. Zeta Potential in Colloid Science: Principles and Applications. Academic Press; 1988.
   Google Scholar
• KattiV, KadamA, HonmaneS, PatilS, PatilS, BhamareK. Improvement of solubility and dissolution rate of candesartan cilexetil by solid dispersion in polyvinyl pyrrolidone. Int J Pharm Sci Res. 2014;5:1550–1556. doi:10.13040/IJPSR.0975-8232.5(4).1550-56
   Google Scholar
• MadyFM, AlyUF. Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins. Drug Des Devel Ther. 2017;11:1681. doi:10.2147/DDDT.S135084
   PubMed Web of Science ®Google Scholar
• LiJ, JiangQ, DengP, et al. The formation of a host-guest inclusion complex system between β-cyclodextrin and baicalin and its dissolution characteristics. J Pharm Pharmacol. 2017;69(6):663–674. doi:10.1111/jphp.1270828299800
   PubMed Web of Science ®Google Scholar
• NtountaniotisD, AndreadelisI, KelliciTF, et al. Host-guest interactions between candesartan and its prodrug candesartan cilexetil in complex with 2-hydroxypropyl-β-cyclodextrin: on the biological potency for angiotensin II antagonism. Mol Pharm. 2019;16(3):1255–1271. doi:10.1021/acs.molpharmaceut.8b0121230681344
   PubMed Web of Science ®Google Scholar